CHICAGO (EGMN)-Cetuximab did not improve overall or progression-free survival when it was added to frontline oxaliplatin-based chemotherapy for metastatic colorectal cancer, according to investigators from the U.K. National Cancer Research Institute."Here's a negative study that ran contrary to what we expected and to what the community expected," said Dr. Timothy S. Maughan, principal investigator for the randomized, phase III COIN trial, at the annual meeting of the American Society of Clinical...